uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease Nasdaq:QURE

uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease Nasdaq:QURE

News Highlights

~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~

~ Company announces plans to initiate a second clinical study of AMT-130 in Europe in the second half of 2021 ~

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 05, 2021 (News) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington’s disease. The Company also announced plans to begin an open-label clinical trial of AMT-130 in Europe later this year.

“This is an important milestone in our ongoing clinical development of AMT-130,” stated David Cooper, M.D., vice president, clinical development at uniQure. “Nine U.S. study sites are now active to support enrollment in the next cohort, which is expected to start after the Data Safety Monitoring Board’s review in the middle of the year. Completing enrollment of the first, 10-patient cohort ahead of schedule highlights the high level of interest among the Huntington’s disease patient and clinical community, and the collaboration between our participating HD Centers of Excellence and the expert neurosurgical sites performing the MRI-guided procedures. We also look forward to initiating a new clinical study of AMT-130 in Europe later this year. It is estimated that there could be as many as 75,000 Europeans affected by Huntington’s disease.”

The ongoing Phase I/II clinical trial of AMT-130 is a randomized, sham controlled, double-blinded study to explore the safety, tolerability, and proof of concept of AMT-130 in patients with early manifest Huntington’s disease. The study, which includes two dose cohorts, will randomize a total of 26 patients to either treatment with AMT-130 or an imitation surgical procedure. The first dose cohort includes 10 patients, of which six patients received treatment with AMT-130 and four patients received imitation surgery. The second dose cohort is planned to include 16 patients, of which 10 patients will receive treatment with AMT-130 and six patients will receive imitation surgery. The trial consists of a blinded 12-month study period followed by unblinded long-term follow-up for 5 years after administration of AMT-130. Patients receive a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).

The planned Phase Ib/II study of AMT-130 will be conducted in Europe and is expected to begin enrolling patients in the second half of 2021. This open-label study will enroll 15 patients with early manifest Huntington’s disease across two dose cohorts. Together with the U.S. study, the European study is intended to establish safety, proof of concept, and the optimal dose of AMT-130 to take forward into Phase III development or into a confirmatory study should an accelerated registration pathway be feasible.  

AMT-130 comprises a recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that lowers Huntingtin protein in Huntington’s disease patients. AMT-130 is uniQure’s first clinical program incorporating its proprietary miQURE™ platform. miQURE is designed to degrade disease-causing genes without off-target toxicity and induce silencing of the entire target organ through secondary exosome-mediated delivery.

About Huntington’s Disease

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, and behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Despite the clear etiology of Huntington’s disease, there are no currently approved therapies to delay the onset or to slow the disease’s progression.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington’s disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, the enrollment of patients in, or Data Safety Monitoring Board review of, our Phase I/II gene therapy clinical trial of AMT-130 in Huntington’s disease, including whether we will be able to fully enroll the second dose cohort as currently planned, and whether we will initiate our P1b/II clinical study of AMT-130 in Europe later this year or ever. uniQure’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with the impact of the ongoing COVID-19 pandemic on our Company and the wider economy and health care system, our Commercialization and License Agreement with CSL Behring, the regulatory approval of that transaction, our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading “Risk Factors” in uniQure’s periodic securities filings, including its Annual Report on Form 10-K filed March 1, 2021. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and uniQure assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

  • Check the latest Health news updates and information.
  • Please share this news uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease Nasdaq:QURE with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Best gaming PC for 2021

Best gaming PC for 2021

Chances are your buying decision has changed over the past several months, whether because you’re anticipating working from home for the long haul or because ...
Time to embrace body cameras for cops

Time to embrace body cameras for cops

While all Illinois police agencies must eventually equip their officers with the body cam technology, small towns like Brookfield had several years to do so. ...
The PlayStation patent would train an AI profile to take control of your games if you need a break

The PlayStation patent would train an AI profile to take control of your games if you need a break

Source As for all tech patents, this application being published does not mean Sony will ever actually put out a product or service that does anything like ...
The Switch Action/Adventure Game Forgotten Gods Has Been Revealed

The Switch Action/Adventure Game Forgotten Gods Has Been Revealed

Nintendo held a live-streamed indie presentation today to announce several new indie games that are coming to the Nintendo Switch. During this showcase, ...
School council postpones sale of Corinne school to consider business proposal by city resident

School council postpones sale of Corinne school to consider business proposal by city resident

Marble acknowledged she was not the highest bidder but hoped the board would see the need for such a facility in this rural community and not make it all about ...
Middlefield Banc Corp.  Reports First Quarter 2021 Financial Results Nasdaq: MBCN

Middlefield Banc Corp. Reports First Quarter 2021 Financial Results Nasdaq: MBCN

Income StatementNet interest income for the 2021 first quarter was $11.9 million, compared to $10.0 million for the 2020 first quarter. The net interest margin ...
The Best iPhone Games for 2021

The Best iPhone Games for 2021

The Apple App Store is loaded with games, but avoiding the dregs can be difficult. Don’t fret, we’re here to help. We’ve highlighted the fun, well-made ...
Super Seducer NFT Debuts Limited Edition Switch ROM

Super Seducer NFT Debuts Limited Edition Switch ROM

It might sound crazy to pay any amount of cash for a unique digital code, but that’s also exactly what cryptocurrency is. (And hey, pretty much most of the ...
Show next
Compsmag - Latest News from tech, business and health
Logo